Drug Trial Radar · NCT07758101
A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Aug 21, 2026
Primary completion
Mar 31, 2028
Study completion Apr 28, 2029
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase I first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-7590 via subcutaneous or intravenous administration in Chinese healthy participants and patients with moderate-to-severe inflammatory bowel disease.
Conditions
- Moderate-to-severe Inflammatory Bowel Disease
Interventions
SHR-7590Drug
SHR-7590
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part1: Adverse eventsTime frame: From ICF signing date to Day 281
- Part1: Serious adverse eventsTime frame: From ICF signing date to Day 281
- Part2: Adverse eventsTime frame: From ICF signing date to Day 393
- Part2: Serious adverse eventsTime frame: From ICF signing date to Day 393
- Part2: Results of 12-lead electrocardiographyTime frame: From ICF signing date to Day 393
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangzhou, China · Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.